Dr Mary Collins
University of Cambridge
나노의약품 개발을 이끄는 핵심 기술과 인사이트
Nanomed Summit 2026에서는 LNP 기반 나노의약품 개발을 둘러싼 최신 트렌드와 실제 현장에서 필요한 기술적 인사이트를 공유합니다.
본 서밋은 나노의약품 개발 과정에서 마주하는 다양한 과제를 기초적인 개념부터 실제 사례 기반의 case study까지 폭넓게 다룹니다. 최신 트렌드를 반영한 CPP·CQA 기반의 공정 요소 소개부터 Lipid 기반 제형 설계 전략, in vivo CAR‑T 등 Lipid 기술을 활용한 신약 개발 접근법, Scale‑up 공정 최적화, 최신 규제와 CMC 대응 전략 등 나노의약품 개발 과정에서 실제로 마주하는 주요 과제와 실무 기반의 해결 전략을 사례 중심으로 소개드릴 예정입니다.
자세한 프로그램은 아래에서 확인하실 수 있으며, Nanomed Summit을 통해 나노의약품 개발을 이끄는 핵심 기술과 인사이트를 얻을 수 있는 기회가 되시기 바랍니다.
※ 본 행사는 참석 확정 안내 메일을 받은 고객님에 한하여 참석이 가능합니다.
※ 현장 내 한정된 좌석으로 인해 참가 신청자를 선별하여 3월 초 참석 확정 안내 메일을 보내드릴 예정입니다.
※ 행사장 주변 혼잡이 예상되오니, 가급적 대중교통을 이용해 주시기 바랍니다.
※ 본 행사는 무료로 진행되며, 점심 식사, 다과 및 기념품이 제공됩니다.
※ Cytiva는 청탁금지법을 준수하며 적용 대상자분들께는 규정에 따른 별도의 식사가 제공될 예정이니 사전에 말씀 부탁 드립니다.
2026년 3월 11일 (수)
서울특별시 서초구 강남대로 213 엘블레스 B1층 골드홀
By attending, you confirm you are not located in or a national of a sanctioned country or region, are not a restricted party, and acknowledge that this training may include content subject to U.S. and other export control and sanctions laws. Sharing the content, whether verbally, visually, electronically, or via screen-sharing during webinars must comply with these laws. Allowing unauthorized or restricted individuals to view or participate is a violation and may result in civil and/or criminal penalties.
| Time | Session |
Speaker |
|---|---|---|
| 10:00 - 10:10 | Opening remark | Heejae Kim |
| 10:10 - 10:50 | LNP 개발 가속화를 위한 최신 공정 워크플로 및 솔루션 소개 | Myungwon Park |
| 10:50 - 11:30 | LNP 공정 개발에서의 CPP·CQA 이해와 적용 전략 | Jeeheon Kang |
| 11:30 - 12:00 | Novel Lipid Libraries 기반 LNP 플랫폼의 기술적 발전과 응용 방법 |
Samuel Clarke |
| 12:00 - 13:00 | Lunch | |
| 13:00 - 13:40 | PCV 및 in vivo, ex vivo 세포치료제 개발을 위한 LNP 전달 기술의 최신 연구 동향 |
Samuel Clarke |
| 13:40 - 14:20 | 유전자 변형 세포 치료제 개발을 앞당기는 최신 LNP 기술과 통합 솔루션 | Sangmin Oh |
|
14:20 - 14:50
|
Tea Break | |
|
14:50 - 15:30
|
mRNA 제조 공정 고도화 전략: IVT·정제부터 LNP 제형화까지 | Soonwoong Choi |
| 15:30 - 16:20 | 나노의약품 규제 최신 트렌드와 CMC 과제 대응 방안 | Ang Wei Xia |
Gene Therapy Workflow Specialist, Cytiva
In 2009, She joined Cytiva as a Field Application Specialist, gaining over 10 years of experience working closely with customers in the protein purification field. Building on this experience, in 2021, she took on the role of Chromatography Product Manager, where I developed strategies and marketing plans tailored to the trends and product characteristics of the Korean market. Currently, as a Gene Therapy Workflow Specialist, she actively introduce Cytiva’s manufacturing processes and portfolio to customers, providing customized product solutions from discovery through to commercialization in the rapidly growing gene therapy field.
Prior to joining Cytiva, she hold a Master’s degree in Protein Engineering from Pusan National University and conducted protein structure research at IBS.
Cell Therapy Field Application Leader, Cytiva
Jeeheon Kang currently serves as the GM Cell Therapy FAS Leader at Cytiva, where she leads technical support for manufacturing equipment used in gene modified cell therapy and lipid nanoparticle (LNP)-based therapeutics. Over the past seven years, she has provided tailored solutions to customers across Korea and the broader Asia-Pacific (APAC) region by identifying and resolving bottlenecks in advanced biopharmaceutical manufacturing processes. Her scientific expertise is grounded in her Ph.D. in Genetic Engineering from Seoul National University, where she studied gene editing, protein expression mechanisms, and intracellular signaling. Additionally, her experience at Asan Medical Center, where she led efficacy evaluation projects for novel drug development, has further strengthened her ability to bridge research and industrial application in her current role.
Director of R&D, Nanomedicine, Cytiva
Dr. Samuel Clarke is an expert in the development of nanoparticles for research, diagnostic and therapeutic applications with more than 15 years’ industry experience in the field. Samuel is currently Director of R&D at Cytiva where he is responsible for the development of lipid nanoparticles for cell therapies and additional therapeutic areas. He has a PhD and post-doc from McGill University and École Normale Supérieure.
Cell Therapy Field Application Specialist, Cytiva
Sangmin Oh holds a Ph.D. in Biomedical Science & Engineering in Hanyang University.
He is an expert on cell therapy R&D and process development who has built his career where cell therapy company. During his tenure at various company, his research focused on stem cells, brain, and immunotherapies, resulting in over 6 publications and a patent. Afterward, he joined Cytiva as a Cell therapy Field Applications Specialist from 2023. His current role focuses on working with sales teams for presales activities that includes demo, seminar to help to generate leads and closure of opportunities. As well as, work to enhance customer experiences of using the equipment thru application/equipment training, customer seminar.
Fast Trak APAC, Downstream Process Development Team Leader, Cytiva
With over twenty years of experience in the biopharmaceutical industry, I began my career at the LG Chemical R&D Institute, where I contributed to end to end biologics development and commercial manufacturing. My expertise spans drug development, process development, and large scale production, supported by hands on involvement across laboratory, preclinical, and commercial GMP operations. I specialize in therapeutic protein manufacturing and possess a deep understanding of both upstream and downstream processes. I currently serve as the Downstream Process Development Manager for Cytiva APAC Fast Trak PDS, leading the downstream team at the Fast Trak Center in Songdo and supporting customers across the region in accelerating biologics development and manufacturing.
Senior Regulatory Compliance Lead, Cytiva
Wei Xia ANG holds a PhD from the National University of Singapore (NUS), specialized in cancer immunotherapy. She is currently responsible for overseeing regulatory compliance at Cytiva and providing regulatory support to customers.
Prior to this role, she served as a regulatory officer with a Singapore government authority, where she reviewed dossiers submitted for clinical trial applications and marketing authorisations. Her regulatory experience spans medicinal products including chemical drugs, biologics, and cell and gene therapy products.
In her previous roles, she also provided regulatory consultation to companies and managed regulatory affairs and international regulatory strategies. Earlier in her research career, she published more than 10 scientific papers and is a co inventor on a patent related to immune cell research.